Tag: Cancer therapy

According to one review, musculoskeletal pain is a frequent side effect of medication, with statins being a well-known example that affects many users. If you're asking, **what kind of medication can cause joint pain?**, it is important to know that several classes of drugs can cause this issue, affecting people differently depending on the specific medication and individual factors.

According to Drugs.com, up to 30% of patients receiving epoetin alfa, a type of erythropoietin (EPO), in clinical trials have experienced diarrhea. While not the most common side effect for all patient groups, it is a significant gastrointestinal issue that can affect individuals undergoing treatment with EPO. Understanding the potential for diarrhea is crucial for patients and healthcare providers managing anemia with erythropoietin-stimulating agents (ESAs).

The incidence of adverse reactions to radiopharmaceuticals is low, estimated at about 2 per 100,000 administrations [1.7.3]. This article explores the question, 'What are the dangers of radiopharmaceuticals?', examining the risks versus the substantial benefits of these medical tools.

Blood clots are a reported serious side effect associated with Herceptin (trastuzumab), though the link is often complex and influenced by other factors inherent to cancer and its treatment. While Herceptin's main side effects typically involve the heart and lungs, patients should be aware of the signs and risks of blood clots during therapy.

Over the past several decades, monoclonal antibody (mAb) therapies have fundamentally transformed the landscape of medical treatment, particularly within oncology. A common use of monoclonal antibodies in medicine is as a highly targeted therapy for certain types of cancer and autoimmune diseases by precisely targeting specific molecules.

According to the National Cancer Institute, adjuvant therapy is an additional cancer treatment given *after* the primary treatment, such as surgery, to lower the risk of recurrence. In contrast, chemotherapy is a specific *type* of drug-based treatment that uses powerful medicines to kill cancer cells throughout the body. The key difference between adjuvant therapy and chemotherapy is one of timing and scope—one is a treatment strategy, and the other is a treatment method.

Immunotoxins are highly potent targeted therapeutic agents that combine a targeting ligand with a bacterial toxin to kill cancer cells. While several have received FDA approval, their market availability and status have evolved over time due to manufacturing issues or commercial decisions.

The term 'delta' appears in many different contexts across science, but in pharmacology and medicine, it can refer to several distinct and critically important concepts. From endogenous receptors that modulate mood and pain to specific cannabinoid compounds and photosensitive agents for cancer, understanding the top 3 deltas provides a fascinating glimpse into diverse therapeutic strategies.

According to the American Association of Oral and Maxillofacial Surgeons (AAOMS), the risk of medication-related osteonecrosis of the jaw (MRONJ) is significantly higher for patients on high-dose intravenous bisphosphonates or denosumab, with incidence ranging from 1% to 10%. This article will explore which of the following medications increases the risk of medication-related osteonecrosis of the jaw, outlining the associated risk factors and management strategies.

Initially mistaken for a type of opioid receptor, the term 'Sigma drug' actually refers to a class of compounds that interact with two distinct protein structures known as sigma-1 and sigma-2 receptors. These receptors are now recognized as novel targets in pharmacology for their roles in diverse physiological and pathological processes.